Positron Emission Tomography (PET) With 3,4-dihydroxy-6-18F-fluoro-L-enylalanine (18F-FDOPA) Study
NCT ID: NCT01248754
Last Updated: 2016-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
20 participants
INTERVENTIONAL
2011-07-31
2014-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
[18F] FDOPA PET Imaging in Glioma: Feasibility Study for PET Guided Brain Biopsy
NCT04870580
18F-FDOPA PET in Neuroendocrine Tumours
NCT02431715
FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma
NCT06172595
Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
NCT01165632
A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas
NCT02104310
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
18F-DOPA PET imaging
Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
Surgical neuronavigation with 18F-DOPA PET imaging
Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Surgical neuronavigation with 18F-DOPA PET imaging
Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Karnofsky Performance status (KPS) ≥ 70
* Age ≥18 years
* Subject is able to understand and consent to study
* Glomerular filtration rate (GFR) ≥ 45 ml/minute
Exclusion Criteria
* Only stereotactic biopsy indicated because tumour is located in eloquent brain.
* The enhancement on the T1 MRI sequence involves or abuts the basal ganglia
* Previous intracranial malignancy or any invasive malignancy unless free of disease \> 5 years
* Prior cranial irradiation
* Contra-indications to systemic radiation exposure: pregnancy or breast feeding
* Subject exceeds the weight limit of the PET scanner bed (204.5 kg)
* Subjects taking medication such as Levodopa for the treatment of Parkinson's Disease
* Allergies or other contraindication to CT contrast or MRI contrast
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alan Nichol
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alan Nichol
Radiation Oncologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alan Nichol, MD
Role: PRINCIPAL_INVESTIGATOR
British Columbia Cancer Agency
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lions Gate Hospital
North Vancouver, British Columbia, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
BC Cancer Agency
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BC Cancer Agency
UBC Department of Surgery
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H10-02888
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.